ACOTEC-B(06669) released its mid-term financial performance with a net profit of 88.577 million yuan, representing a year-on-year increase of 121.7%.
Sino Biopharmaceutical Limited (06669) released its performance for the six months ending on June 30, 2025. During the period, the group achieved...
ACOTEC-B (06669) released its performance for the six months ending June 30, 2025. The group made a revenue of 351 million RMB during the period, an increase of 20.1% compared to the previous year. The net profit for the period was 88.577 million RMB, a 121.7% increase compared to the previous year. The basic earnings per share was 0.29 RMB.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
